Allogene Therapeutics ALLO Change in Other Assets
Change in Other Assets at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentAssets.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's change in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's change in other assets?
- Allogene Therapeutics (ALLO) reported change in other assets of -$84K in Q1 2026.
- How has Allogene Therapeutics's change in other assets changed year-over-year?
- Allogene Therapeutics's change in other assets increased by 80.2% year-over-year, from -$425K to -$84K.
- What is the long-term trend for Allogene Therapeutics's change in other assets?
- Over 2 years (2022 to 2024), Allogene Therapeutics's change in other assets has grown at a 8.3% compound annual growth rate (CAGR), from $3.65M to -$4.28M.
- What does change in other assets mean?
- Change in miscellaneous assets affecting operating cash flow.